Cargando…

Inhibition of IGF-IR tyrosine kinase induces apoptosis and cell cycle arrest in imatinib-resistant chronic myeloid leukaemia cells

Although signalling through the type I insulin-like growth factor receptor (IGF-IR) maintains the survival of haematopoietic cells, a specific role of IGF-IR in haematological neoplasms remains largely unknown. Chronic myeloid leukaemia (CML) is the most common subtype of chronic myeloproliferative...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shi, Ping, Chandra, Joya, Sun, Xiaoping, Gergely, Mate, Cortes, Jorge E, Garcia-Manero, Guillermo, Arlinghaus, Ralph B, Lai, Raymond, Amin, Hesham M
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Blackwell Publishing Ltd 2010
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3444523/ https://www.ncbi.nlm.nih.gov/pubmed/19508387 http://dx.doi.org/10.1111/j.1582-4934.2009.00795.x

Ejemplares similares

Expression of insulin receptor (IR) A and B isoforms, IGF-IR, and IR/IGF-IR hybrid receptors in vascular smooth muscle cells and their role in cell migration in atherosclerosis
por: Beneit, N., et al.
Publicado: (2016)

Dual inhibition of IGF-IR and ALK as an effective strategy to eradicate NPM-ALK(+) T-cell lymphoma
por: George, Bhawana, et al.
Publicado: (2019)

IGF-IR signaling in epithelial to mesenchymal transition and targeting IGF-IR therapy: overview and new insights
por: Li, Heming, et al.
Publicado: (2017)

Efficacy and safety of generic imatinib after switching from original imatinib in patients treated for chronic myeloid leukemia in the United States
por: Abou Dalle, Iman, et al.
Publicado: (2019)

Correction: Dual inhibition of IGF-IR and ALK as an effective strategy to eradicate NPM-ALK(+) T-cell lymphoma
por: George, Bhawana, et al.
Publicado: (2023)

Managing chronic myeloid leukaemia in the elderly with intermittent imatinib treatment
por: Russo, D, et al.
Publicado: (2015)

Novel cross-talk between IGF-IR and DDR1 regulates IGF-IR trafficking, signaling and biological responses
por: Malaguarnera, Roberta, et al.
Publicado: (2015)

The transcription factors Ik-1 and MZF1 downregulate IGF-IR expression in NPM-ALK(+) T-cell lymphoma
por: Vishwamitra, Deeksha, et al.
Publicado: (2015)

IGF-IR Internalizes with Caveolin-1 and PTRF/Cavin in Hacat Cells
por: Salani, Barbara, et al.
Publicado: (2010)

Rotating between ponatinib and imatinib temporarily increases the efficacy of imatinib as shown in a chronic myeloid leukaemia model
por: Lindström, H. Jonathan G., et al.
Publicado: (2022)

Time-dependent effects of imatinib in human leukaemia cells: a kinetic NMR-profiling study
por: Klawitter, J, et al.
Publicado: (2009)

Alterations of Gab2 signalling complexes in imatinib and dasatinib treated chronic myeloid leukaemia cells
por: Halbach, Sebastian, et al.
Publicado: (2013)

Downregulation of the histone methyltransferase SETD2 promotes imatinib resistance in chronic myeloid leukaemia cells
por: Sheng, Yaru, et al.
Publicado: (2019)

Interaction between IGF-IR and ER Induced by E2 and IGF-I
por: Yu, Zhenghong, et al.
Publicado: (2013)

Disease acceptance and adherence to imatinib in Taiwanese chronic myeloid leukaemia outpatients
por: Chen, Li-Chia, et al.
Publicado: (2013)

Recent developments in the structural characterisation of the IR and IGF1R: implications for the design of IR–IGF1R hybrid receptor modulators
por: Turvey, Samuel J., et al.
Publicado: (2022)

Effectiveness of imatinib mesylate over etoposide in the treatment of sensitive and resistant chronic myeloid leukaemia cells in vitro
por: Husaini, Roslina, et al.
Publicado: (2017)

The Role of IGF/IGF-IR-Signaling and Extracellular Matrix Effectors in Bone Sarcoma Pathogenesis
por: Tzanakakis, George N., et al.
Publicado: (2021)

IGF-IR determines the fates of BCR/ABL leukemia
por: Xie, Jingjing, et al.
Publicado: (2015)

IGF-IR Targeted Therapy: Past, Present and Future
por: Janssen, Joseph A. M. J. L., et al.
Publicado: (2014)

Tyrosine kinase inhibitor imatinib augments tumor immunity by depleting effector regulatory T cells
por: Tanaka, Atsushi, et al.
Publicado: (2019)

Imatinib adherence associated clinical outcomes of chronic myeloid leukaemia treatment in Taiwan
por: Chen, Teng-Chou, et al.
Publicado: (2013)

Modelling Predictors of Molecular Response to Frontline Imatinib for Patients with Chronic Myeloid Leukaemia
por: Banjar, Haneen, et al.
Publicado: (2017)

Stimulatory actions of IGF-I are mediated by IGF-IR cross-talk with GPER and DDR1 in mesothelioma and lung cancer cells
por: Avino, Silvia, et al.
Publicado: (2016)

Rosiglitazone Inhibits Adrenocortical Cancer Cell Proliferation by Interfering with the IGF-IR Intracellular Signaling
por: Cantini, Giulia, et al.
Publicado: (2008)

IRS-1 acts as an endocytic regulator of IGF-I receptor to facilitate sustained IGF signaling
por: Yoneyama, Yosuke, et al.
Publicado: (2018)

Feasibility of treatment-free remission with generic imatinib: Results of generic imatinib-free trial-in-chronic myeloid leukaemia-chronic phase study
por: Goni, Deepak, et al.
Publicado: (2023)

Cytokinesis arrest and multiple centrosomes in B cell chronic lymphocytic leukaemia
por: Rogne, Marie, et al.
Publicado: (2018)

The novel IGF-IR/Akt–dependent anticancer activities of glucosamine
por: Song, Ki-Hoon, et al.
Publicado: (2014)

Cross-Talk between Adiponectin and IGF-IR in Breast Cancer
por: Mauro, Loredana, et al.
Publicado: (2015)

IGF-IR: a new prognostic biomarker for human glioblastoma
por: Maris, C, et al.
Publicado: (2015)

Cost–utility analysis of imatinib mesilate for the treatment of advanced stage chronic myeloid leukaemia
por: Gordois, A, et al.
Publicado: (2003)

Hyperpigmentation of the hard palate mucosa in a patient with chronic myeloid leukaemia taking imatinib
por: Bombeccari, Gian Paolo, et al.
Publicado: (2017)

Purification of Bone Marrow Clonal Cells from Patients with Myelodysplastic Syndrome via IGF-IR
por: He, Qi, et al.
Publicado: (2015)

IGF-IR promotes clonal cell proliferation in myelodysplastic syndromes via inhibition of the MAPK pathway
por: He, Qi, et al.
Publicado: (2020)

Retraction: Carboxyamidotriazole-Orotate Inhibits the Growth of Imatinib-Resistant Chronic Myeloid Leukaemia Cells and Modulates Exosomes-Stimulated Angiogenesis
Publicado: (2019)

Tyrosine Kinase Inhibitor Imatinib Mesylate Alters DMBA-Induced Early Onco/Suppressor Gene Expression with Tissue-Specificity in Mice
por: Gergely, Péter Attila, et al.
Publicado: (2019)

Factors influencing long‐term efficacy and tolerability of bosutinib in chronic phase chronic myeloid leukaemia resistant or intolerant to imatinib
por: Brümmendorf, Tim H., et al.
Publicado: (2015)

Preclinical and phase I clinical studies of KW-2450, a dual IGF-1R/IR tyrosine kinase inhibitor, in combination with lapatinib and letrozole
por: Umehara, Hiroshi, et al.
Publicado: (2018)

MAP3K4 promotes fetal and placental growth by controlling the receptor tyrosine kinases IGF1R/IR and Akt signaling pathway
por: Perry, Charles H., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_qnhr93s5arss2oj406sm06arqs